New York City hospitals will not renew Palantir contract over medical data access dispute

New York's municipal hospital system has decided not to renew its contract with Palantir, which expires in October 2026. The decision appears local, but is actually part of a broader discussion about how far AI companies can go in working with government and healthcare data.

Why the contract is being closed

NYC Health + Hospitals President and CEO Mitchell Katz told the city council that the agreement with Palantir will end in October 2026 and will not be renewed. According to him, the project was originally conceived as temporary. It was not related to clinical diagnostics, but rather to optimizing insurance calculations: Palantir helped the hospital system find underpaid reimbursements and more accurately file claims under programs like Medicaid.

Since November 2023, the company received nearly $4 million for this work. After the contract expires, the system will transition to its own internal solutions. NYC Health + Hospitals separately emphasized that after October, they will neither transfer data to Palantir nor use the company's applications.

Hospital leadership also insists that the contractor's work was strictly limited to financial and administrative tasks, and that there was an "absolute firewall" between Palantir and federal immigration service ICE. According to Katz, there were no incidents involving unauthorized access during the collaboration.

What concerned critics

The disputes were triggered not so much by the fact of automation itself, but by the scope of access and the wording in the documents. Under the contract terms, Palantir could review notes about patients' health status to help hospitals recover more money under government programs. Additionally, the documents contained a clause allowing de-identification of protected health information and its use "for purposes other than research" — with permission from the city agency. Precisely this clause became the main alarm bell for critics.

• access to patient health notes for financial optimization
• ability to work with de-identified data outside research tasks
• Palantir's broad presence in contracts with US and UK government agencies
• platform's ability to connect and analyze large volumes of heterogeneous data

Lawyers and privacy experts say that de-identification alone is no longer sufficient as a safety guarantee. The more powerful the analytical and AI tools, the easier it is to re-match de-identified data with specific individuals if other large databases are nearby. Palantir, for its part, responds that it does not own client data, does not receive rights to it, and works only within the customer's instructions. But the dispute here is not only about the current contract, but about what capabilities become available to the contractor and the state in the future.

Pressure in the US and Britain

New York's decision was a victory for the Purge Palantir activist campaign. Pressure on the city was intensified by nurses, pro-Palestinian activists, as well as social and climate organizations. They argued that a company whose technologies are used by American immigration authorities and military structures should not work within public medicine. For them, the problem was not only the risks of data leaks, but also the political and military connections that come with the contractor.

"De-identification no longer provides the guarantee it once did, and with AI capabilities, re-identification becomes easier," — law professor

Sharon Hoffman.

Against this backdrop, the story quickly spread beyond New York, because in Britain Palantir is just expanding its influence. The company has already received a £330 million NHS England contract for the Federated Data Platform, and also participates in Ministry of Defence projects and is trying to gain access to sensitive financial regulator FCA data. British critics point out that by last summer, Palantir technology had been implemented by fewer than half of the country's healthcare bodies, and Medact and Amnesty International UK urge NHS to follow New York's example and break the deal.

What this means

The Palantir story shows that for AI suppliers in the public sector, it is no longer enough to promise savings and efficiency. Contracts are now evaluated by a different set of criteria: who gets access to data, whether it is safe to exit dependence on the contractor, and whether patients and society trust this. New York demonstrated that even a major government contract can be declined if political and reputational risks begin to outweigh the benefits.